Kolon TissueGene, Inc. (950160.KQ)
KRW 23000.0
(-5.35%)
KRW 23000.0
(-5.35%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -24.1 Billion | -26.77 Billion | -40.01 Billion | -38.12 Billion | - |
| Net Income | -17.22 Billion | -11.13 Billion | -47.36 Billion | -41.78 Billion | - |
| Depreciation & Amortization | 1.41 Billion | 1.66 Billion | 1.55 Billion | 1.64 Billion | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 77.11 Million | - | - | 1.32 Million | 24.5 Million |
| Change in working capital | -7.67 Billion | -11.89 Billion | 4.96 Billion | 803.39 Million | - |
| Other non-cash items | -3.14 Billion | -4.97 Billion | 336.15 Million | -40.98 Million | - |
| Investing Cash Flow | -29.03 Billion | -40.05 Billion | 33.41 Billion | 18.7 Billion | - |
| Investments in PPE | -46.19 Billion | -24.34 Billion | -6.13 Billion | -839.64 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -26.6 Billion | -17 Billion | -1.32 Billion | -41 Billion | - |
| Sales/Maturities of investments | 43.8 Billion | 1.45 Billion | 40.9 Billion | 60.68 Billion | - |
| Other Investing Activities | -39.23 Million | -156.37 Million | -89.33 Million | -128 Million | - |
| Financing Cash Flow | 38.1 Billion | 66.9 Billion | 24.58 Billion | -6.88 Billion | - |
| Debt repayment | - | - | -8.58 Billion | -5.9 Billion | -5.82 Billion |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 39.26 Billion | 37.36 Billion | 34.22 Billion | - | 233.13 Million |
| Other Financing Activities | -1.16 Billion | 30.64 Billion | - | - | - |
| Accounts receivables | -120.38 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | -47.42 Million | 89.38 Million | 124.4 Million | 61.73 Million | - |
| Other working capital | -7.5 Billion | - | - | - | - |
| Cash at beginning of period | 42.81 Billion | 42.29 Billion | 19.48 Billion | 46.39 Billion | - |
| Cash at end of period | 27.77 Billion | 42.37 Billion | 37.46 Billion | 20.08 Billion | -357.59 Million |
| Capital Expenditure | -46.19 Billion | -24.34 Billion | -6.13 Billion | -839.64 Million | - |
| Effect of forex changes on cash | 6.64 Million | -4.42 Million | 5.08 Million | - | -357.59 Million |
| Net cash flow / Change in cash | -15.03 Billion | 72.75 Million | 17.98 Billion | -26.3 Billion | -357.59 Million |
| Free Cash Flow | -70.3 Billion | -51.11 Billion | -46.15 Billion | -38.96 Billion | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -5.33 Billion | -3.78 Billion | -17.22 Billion | -3.89 Billion | -4.44 Billion | -4.98 Billion |
| Depreciation & Amortization | 215.69 Million | 226.03 Million | 1.41 Billion | 130.93 Million | 437.3 Million | 427.51 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 15.8 Million | 21.25 Million | 77.11 Million | 26.45 Million | 5.98 Million | 38.96 Million |
| Change in working capital | -649.06 Million | -1.6 Billion | -7.67 Billion | 7.34 Billion | -9.58 Billion | -1.27 Billion |
| Other non-cash items | -190.48 Million | -148.97 Million | -3.14 Billion | -1.69 Billion | -689.99 Million | -511.05 Million |
| Investing Cash Flow | -18.38 Billion | -10.94 Billion | -29.03 Billion | 128.06 Million | -2.23 Billion | -37.03 Billion |
| Investments in PPE | -18.41 Billion | -10.94 Billion | -46.19 Billion | -25.91 Billion | -2.53 Billion | -11.05 Billion |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -26.6 Billion | -17.03 Billion | -237.34 Million | - |
| Sales/Maturities of investments | - | - | 43.8 Billion | 43.1 Billion | 500 Million | -16.6 Billion |
| Other Investing Activities | 35.08 Million | 5.24 Million | -39.23 Million | -33.94 Million | 27.65 Million | -33.66 Million |
| Financing Cash Flow | 46.11 Billion | -305.98 Million | 38.1 Billion | -150.4 Million | -140.26 Million | 38.64 Billion |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 39.26 Billion | 153.1 Million | 160.93 Million | 38.93 Billion |
| Other Financing Activities | 611 Thousand | -610 Thousand | - | - | - | - |
| Accounts receivables | 364.67 Million | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | -37.99 Million | 8.04 Million | -47.42 Million | -21.09 Million | 16.41 Million | -43.67 Million |
| Other working capital | -975.74 Million | - | - | - | - | - |
| Cash at beginning of period | 11.87 Billion | 28.26 Billion | 42.81 Billion | 24.81 Billion | 40.74 Billion | 44.28 Billion |
| Cash at end of period | 34.28 Billion | 11.87 Billion | 27.77 Billion | 27.77 Billion | 24.81 Billion | 40.74 Billion |
| Capital Expenditure | -18.41 Billion | -10.94 Billion | -46.19 Billion | -25.91 Billion | -2.53 Billion | -11.05 Billion |
| Effect of forex changes on cash | -15.85 Million | -27.52 Million | 6.64 Million | 35.77 Million | -25.05 Million | -2.32 Million |
| Net cash flow / Change in cash | 22.4 Billion | -16.38 Billion | -15.03 Billion | 2.95 Billion | -15.93 Billion | -3.53 Billion |
| Free Cash Flow | -24.17 Billion | -16.05 Billion | -70.3 Billion | -23.13 Billion | -16.23 Billion | -16.83 Billion |
129260
JELLF
YUKEN
RSE
CANSF
293780